Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells

CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio

(2015) S. E. Bates et al.   CLINICAL CANCER RESEARCH

Romidepsin for the treatment of non-Hodgkin’s lymphoma

(2015) Victor Y Yazbeck et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Promising therapies for the treatment of chronic lymphocytic leukemia

(2015) Fortunato Morabito et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Treatment options for mantle cell lymphoma

(2015) Piotr Smolewski et al.   EXPERT OPINION ON PHARMACOTHERAPY

Emerging drugs for diffuse large B-cell lymphoma

(2015) Patrizia Mondello et al.   Expert Review of Anticancer Therapy

Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?

(2015) Jennifer K. Lue et al.   Current Oncology Reports

Cutaneous T-cell lymphoma: 2014 Update on diagnosis, risk-stratification, and management

(2014) Ryan A. Wilcox   AMERICAN JOURNAL OF HEMATOLOGY

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma

(2014) C. Correia et al.   BLOOD

Histone deacetylase inhibitors and cell death

(2014) Jing Zhang et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Histone Deacetylase Inhibitor Sensitizes Apoptosis-Resistant Melanomas to Cytotoxic Human T Lymphocytes through Regulation of TRAIL/DR5 Pathway

(2014) A. R. Jazirehi et al.   JOURNAL OF IMMUNOLOGY

Bak Core and Latch Domains Separate during Activation, and Freed Core Domains Form Symmetric Homodimers

(2014) Jason M. Brouwer et al.   MOLECULAR CELL

Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights

(2014) Prithviraj Bose et al.   PHARMACOLOGY & THERAPEUTICS

Genetics of Follicular Lymphoma Transformation

(2014) Laura Pasqualucci et al.   Cell Reports

Bax Crystal Structures Reveal How BH3 Domains Activate Bax and Nucleate Its Oligomerization to Induce Apoptosis

(2013) Peter E. Czabotar et al.   CELL

Evaluation of the BH3-only Protein Puma as a Direct Bak Activator

(2013) Haiming Dai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Changing Landscape of Peripheral T-Cell Lymphoma in the Era of Novel Therapies

(2013) Lionel Karlin et al.   SEMINARS IN HEMATOLOGY

Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells

(2012) D. Merino et al.   BLOOD

Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis

(2012) Simone Fulda   EXPERIMENTAL CELL RESEARCH

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

(2011) M. Gupta et al.   BLOOD

Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation

(2011) H. Ding et al.   BLOOD

Deciphering the Molecular Events Necessary for Synergistic Tumor Cell Apoptosis Mediated by the Histone Deacetylase Inhibitor Vorinostat and the BH3 Mimetic ABT-737

(2011) A. P. Wiegmans et al.   CANCER RESEARCH

Vorinostat-Induced Apoptosis in Mantle Cell Lymphoma Is Mediated by Acetylation of Proapoptotic BH3-Only Gene Promoters

(2011) S. Xargay-Torrent et al.   CLINICAL CANCER RESEARCH

Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases

(2011) Andreas Strasser et al.   EMBO JOURNAL

High Cell Surface Death Receptor Expression Determines Type IVersusType II Signaling

(2011) Xue Wei Meng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Noxa/Bcl-2 Protein Interactions Contribute to Bortezomib Resistance in Human Lymphoid Cells

(2011) Alyson J. Smith et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization

(2011) Haiming Dai et al.   JOURNAL OF CELL BIOLOGY

A Unified Model of Mammalian BCL-2 Protein Family Interactions at the Mitochondria

(2011) Fabien Llambi et al.   MOLECULAR CELL

Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions

(2010) Paul A. Marks   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells

(2010) R Shimizu et al.   LEUKEMIA

Different forms of cell death induced by putative BCL2 inhibitors

(2009) M Vogler et al.   CELL DEATH AND DIFFERENTIATION

Context-dependent Bcl-2/Bak Interactions Regulate Lymphoid Cell Apoptosis

(2009) Haiming Dai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

βTrCP- and Rsk1/2-Mediated Degradation of BimEL Inhibits Apoptosis

(2009) Elinor Dehan et al.   MOLECULAR CELL

Bim and Bmf in tissue homeostasis and malignant disease

(2009) J D Piñon et al.   ONCOGENE

Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate

(2008) Y. Dai et al.   BLOOD

Anticancer therapy: boosting the bang of Bim

(2008) Andrea Wahner Hendrickson et al.   JOURNAL OF CLINICAL INVESTIGATION

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

(2008) Mark S. Cragg et al.   JOURNAL OF CLINICAL INVESTIGATION

Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin

(2008) A. Newbold et al.   MOLECULAR CANCER THERAPEUTICS

Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist

(2008) A. J. Frew et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Apoptosis: controlled demolition at the cellular level

(2007) Rebecca C. Taylor et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY